Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03020888
Other study ID # US-002
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2017
Est. completion date July 2018

Study information

Verified date January 2021
Source Endomagnetics Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this post-marketing study is to provide prospective evidence that the Magseed and Sentimag® is effective for lesion localization in patients undergoing surgical excision of a breast lesion and to summarize measures of product safety and performance.


Description:

This is a post-market, prospective, open label, single arm study of Magseed and Sentimag in patients undergoing surgical excision of a breast lesion. Subjects will have the Magseed marker deployed under imaging guidance up to thirty days prior to surgery. The Magseed marker will be localized using the Sentimag system during surgery and removed with the lesion. After the lumpectomy procedure, subjects will be evaluated for safety and patient reported outcomes.


Other known NCT identifiers
  • NCT03019445

Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date July 2018
Est. primary completion date February 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects with a breast lesion requiring image-guided localization prior to excision. - Subjects aged 18 years or more at the time of consent. Exclusion Criteria: - The subject is pregnant or lactating. - Subject has pacemaker or other implantable device in the chest wall. - Subject has current active infection at the implantation site in the breast (per investigatordiscretion)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Magseed and Sentimag
Magseed marker and Sentimag probe for lesion localization

Locations

Country Name City State
United States University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
Endomagnetics Inc M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of Participants With Retrieval of Index Lesion and Magseed Percent retrieval rate of the index lesion and Magseed in the initial excised specimen. This is defined as the number of subjects in whom the index lesion and Magseed are retrieved in the initial excised specimen divided by the total number of subjects undergoing surgery. Time of surgery on average 16 minutes
Secondary Number of Device Related Adverse Events Rates of device-related adverse events and device-related serious adverse events 8 weeks
Secondary Percent of Participants With Radiological Ease of Placement Rated as Very Easy, or Fairly Easy Radiologist were asked to rate ease of marker placement graded from Very easy, Fairly Easy & Difficult after each marker placement. At the time of marker deployment on average 8.39 minutes
Secondary Percentage of Markers With Radiological Placement Accuracy Measured as <5mm to Lesion Success rate of Magseed placement relative to the lesion (placement accuracy) measured as <5mm to lesion; 5-10mm to lesion; >10 mm to the target At time of marker deployment on average 8.39 minutes
Secondary Percentage of Participants With Re-excision Overall re-excision rate and re-excision rate necessary to remove the Magseed or targeted lesion During surgery on average 16 minutes
Secondary Percent of Participants With Surgical Ease of Localization - Rated Fairly or Very Easy Surgeon rated ease of localization during surgery assessed for each procedure as either very easy, fairly easy, fairly difficult, difficult, unable to localise At time of surgery on average 16 minutes
Secondary Surgical Localization - Duration of Localization Duration of the lumpectomy procedure, time taken to remove the lesion At time of surgery on average 16 minutes
Secondary Percentage of Participants With Marker Retrieval Rated as Fairly or Very Easy Pathologist rated ease of marker identification and retrieval as: 1) Unable to retrieve 2) Difficult 3) Fairly difficult 4)fairly easy 5) very easy On the day of surgery
See also
  Status Clinical Trial Phase
Terminated NCT03520127 - A Registry Study Evaluating Outcomes in Breast Biopsy With the Intactâ„¢ Breast Lesion Excision System (BLES)
Active, not recruiting NCT03706534 - Breast Ultrasound Image Reviewed With Assistance of Deep Learning Algorithms N/A
Completed NCT00599105 - Angiogenesis in Early Breast Cancer for Prognosis Prediction N/A
Recruiting NCT01368939 - Investigation of High Resolution Nuclear Breast Imaging Camera (MBI) in Patients Administered Tc-99m Sestamibi (ROSE) N/A
Terminated NCT00934297 - Visualization Tool for Investigation of Breast Lesions N/A
Unknown status NCT00671385 - Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning N/A
Recruiting NCT05118295 - Single Step Lesion Annotation and Localization of Suspicious Breast Lesions Early Phase 1